1. Ownership (As on May 29, 2012) ● XXX is dedicated to the development and provision of innovative immunoassays for use in clinical and research laboratories ● Supplies specialist immunoassay kits and automated immunoanalyser technologies for use in research, medical and pharmaceutical applications ● In FY’11, 167 IDS-iSYS systems were sold / placed on a reagent rental basis by the Company ● Organised into following reportable segments: − Based on products: Vitamin D (55.5%), Automation (20.6%), Octeia (4.3%), Gamma B (1.5%), Distribution of third-party sales (3.4%), Nordic Bioscience (7.7%), Biocode Hycel (3%) and Others (3.9%) − Based on geography: UK (25.7%), Europe (36.9%) and USA (37.3%) ● Has 3 manufacturing sites in Europe; France, the UK and Belgium ● Operates through subsidiaries in the US, Germany, France and Denmark ● Other markets are serviced through a network of 39 distributors covering 28 countries ● Founded: 1947; Headquartered: Boldon, UK; Employees: 294; Status: Public (AIM:IDH) XXX enjoys a leading position in the provision of immunoassay kits for the determination of vitamin D Business Description Financials Company Overview Shareholders% held Forum Venture Capital 27.08 Schroder Investment Managers 10.98 Black Rock, Inc. 10.46 Newton Investment Management Ltd 5.80 Dr R T Duggan 5.41 HSBC Trinkaus & Burkhardt 3.60 Others 36.67 ● In 2011, turnover increased by 35% (y-o-y) to £50.2m compared to £37.2m in 2010 − Due to significant growth in sales of automated IDS-iSYS products coupled with large accounts secured in the US Directors & Executives Board of Directors NameTitle Anthony MartinNon-Executive Chairman Patrik DahlenCEO Martha GarrityTechnical Director Gerard MurrayGroup Finance Director Alain RousseauEngineering Director Eddie BlairNon-Executive Director Burkhard WittekNon-Executive Director Roland SackersNon-Executive Director Senior Executives NameTitle Kenneth GibbsCEO and MD, USA Ed CoombesCountry Manager, France Dagmar KasperCountry Manager, Northern Europe Rudolf SchemerCountry Manager, Germany 1 FYE 31 Mar, £ m 2008A2009A2010A2011A2012E2013E2014E CAGR 08-11 CAGR 11-14E Revenue16.524.937.250.252.754.960.045.0%6.1% % growth66.0%51.4%49.0%35.0%5.1%4.2%9.3% EBITDA 5.3 7.0 15.0 21.0 19.3 21.523.258.7%3.4% % margin31.9%28.0%40.4%41.9%36.6%39.2%38.7% D & A 0.9 1.4 3.4 3.8 4.6 4.9 5.159.9%10.2% % sales5.7% 9.0%7.6%8.7%8.9%8.5% Capex (1) 3.15.7 7.0 8.2 6.7 6.6 37.7%(6.9%) % sales19.0%23.1%18.8%16.3%12.7%12.0%11.0%

2. Segments Description IDS Overview ● Has direct presence in Scandinavia, Germany and France through offices in Copenhagen supporting Scandinavia and the Baltic States; Frankfurt supporting Germany, Austria, Switzerland and Eastern Europe; Paris supporting French market ● Has 2 manufacturing sites in Europe located in France and Belgium ● Operates through two distribution hubs, the first in UK supporting UK, Scandinavian and export customers and the second in central Germany supporting Eurozone customers ● Houses manual and automated reagent development, manufacturing and sales operations ● In 2011, UK domestic sales accounted for only 5% of IDS’ total sales, rest of the sales were generated from export ● Supports UK, Scandinavian and export customers through the distribution hub located in UK ● Established as Immunodiagnostic Systems Inc in January 2003 ● Collaborates with companies who market and sell open-menu automated systems ● In 2010, the receipt of 510(k) clearances enables IDS to market the IDS-iSYS, a fully-automated closed immunoassy system and its flagship product, 25-Hydroxy Vitamin D, in the US laboratories undertaking analyses for human diagnostic purposes ● Has a distribution hub in Scottsdale, Arizona supporting US customers Financial Performance ● Revenue growth CAGR (2006-11): 65.2% ● In 2011, revenue of the segment increased by 56% (y-o-y) and reached £18.7m; while, profit before tax declined by 40% (y-o-y) before adjustments − Growth in revenue was mainly due to acquisition of larger accounts in the US ● Revenue growth CAGR (2006-11): 64.9% ● In 2011, revenue of the segment increased by 22.7% (y-o-y) and reached £18.5m along with increase in profit before tax by 305% (y-o-y) before adjustments − Direct sales operations recorded a growth of 29% to £10.1m in France and 31% to £6.0m in Germany ● Revenue growth CAGR (2006-11): 20.4% ● In 2011, revenue of the segment increased by 28.3% (y-o-y) and reached £12.9m along with increase in profit before tax by 61.7% (y-o-y) before adjustments USA (37.3%) Europe (36.9%) UK (25.7%) 2 Source: Company data